Status:

COMPLETED

Effects of Doxazosin Gastrointestinal Therapeutic System on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensive Patients

Lead Sponsor:

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Conditions:

Hypertension

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The primary objective was to determine the effects of the Gastrointestinal Therapeutic System (GITS) formulation of Doxazosin when used in combination therapy with the 5 major classes of antihypertens...

Eligibility Criteria

Inclusion

  • Eligible subjects were males or females ≥18 years of age with a diagnosis of primary essential hypertension and currently taking 1 or 2 individual antihypertensive agents
  • Dosing for entry antihypertensive medication was at the accepted efficacious dose or the maximum tolerated dose and had to be stable for at least 4 weeks prior to study entry
  • Subjects were required to have clinic sitting DBP ≥95 and ≤110 mmHg and SBP ≥140 and ≤180 mmHg as an average of 3 readings on their current antihypertensive therapy at visits 1 and 2

Exclusion

  • Exclusion criteria included, but were not limited to:
  • Subjects taking antihypertensive medications for other indications (i.e. arrhythrma, unstable angina, CHF, etc.)
  • Orthostatic hypotension, defined as a decrease of at least 20 mmHg systolic or 1OmmHg diastolic pressure between sitting and standing blood pressures after 2 rmnutes, or known fluid depletion.

Key Trial Info

Start Date :

February 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2004

Estimated Enrollment :

89 Patients enrolled

Trial Details

Trial ID

NCT00646841

Start Date

February 1 2003

End Date

February 1 2004

Last Update

January 29 2021

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Pfizer Investigational Site

Brescia, Italy, 25123

2

Pfizer Investigational Site

Monza (Milan), Italy, 20052

3

Pfizer Investigational Site

Padua, Italy, 35128

4

Pfizer Investigational Site

Palamós, Gerona, Spain, 17230